Pharma Equity Group A/S (CHIX:PEGC) EV-to-EBIT : -11.10 (As of May. 04, 2024)

View and export this data going back to 2016. Start your Free Trial

What is Pharma Equity Group A/S EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Pharma Equity Group A/S's Enterprise Value is kr280.70 Mil. Pharma Equity Group A/S's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was kr-25.28 Mil. Therefore, Pharma Equity Group A/S's EV-to-EBIT for today is -11.10.

The historical rank and industry rank for Pharma Equity Group A/S's EV-to-EBIT or its related term are showing as below:

CHIX:PEGc' s EV-to-EBIT Range Over the Past 10 Years
Min: -42.67 Med: -17.48 Max: -10.74
Current: -11.1

During the past 13 years, the highest EV-to-EBIT of Pharma Equity Group A/S was -10.74. The lowest was -42.67. And the median was -17.48.

CHIX:PEGc's EV-to-EBIT is ranked worse than
100% of 434 companies
in the Biotechnology industry
Industry Median: 8.915 vs CHIX:PEGc: -11.10

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Pharma Equity Group A/S's Enterprise Value for the quarter that ended in Dec. 2023 was kr1,046.38 Mil. Pharma Equity Group A/S's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was kr-25.28 Mil. Pharma Equity Group A/S's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -2.42%.

Pharma Equity Group A/S EV-to-EBIT Historical Data

The historical data trend for Pharma Equity Group A/S's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharma Equity Group A/S EV-to-EBIT Chart

Pharma Equity Group A/S Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-EBIT

Get a 7-Day Free Trial

-4.16

-1.23

6.57

-3.52

-18.43

Pharma Equity Group A/S Quarterly Data
	Mar16	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EV-to-EBIT	Get a 7-Day Free Trial															-3.52	-60.89	-43.70	-28.78	-18.43

Competitive Comparison of Pharma Equity Group A/S's EV-to-EBIT

For the Biotechnology subindustry, Pharma Equity Group A/S's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Pharma Equity Group A/S's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pharma Equity Group A/S's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Pharma Equity Group A/S's EV-to-EBIT falls into.

Pharma Equity Group A/S EV-to-EBIT Calculation

Pharma Equity Group A/S's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	280.704	/	-25.279
	=	-11.10

Pharma Equity Group A/S's current Enterprise Value is kr280.70 Mil.
Pharma Equity Group A/S's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-25.28 Mil.

Pharma Equity Group A/S (CHIX:PEGc) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Pharma Equity Group A/S's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 )	=	EBIT	/	Enterprise Value (Q: Dec. 2023 )
	=	-25.279	/	1046.382625
	=	-2.42 %

Pharma Equity Group A/S's Enterprise Value for the quarter that ended in Dec. 2023 was kr1,046.38 Mil.
Pharma Equity Group A/S's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-25.28 Mil.

Pharma Equity Group A/S EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Pharma Equity Group A/S's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Pharma Equity Group A/S (CHIX:PEGC) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharma Equity Group A/S (CHIX:PEGc) » Definitions » EV-to-EBIT

Comparable Companies

Traded in Other Exchanges

PEG:Denmark

Address

Slotsmarken 18, 2.th., Horsholm, DNK, DK-2970

Website

https://www.pharmaequitygroup.com

Pharma Equity Group A/S is an investment company specializing in the life science industry. The group is focused on an early investment in various life science companies that develops technologies and therapies that have the potential to improve human health and quality of life. The group specializes in early-stage investments in biotechnology, that are developing novel therapies for unmet medical needs. Its portfolio consists of companies dedicated to developing novel, effective treatments for diseases with patient and social impact for which current therapy is lacking or in need of improvement.

Pharma Equity Group A/S (CHIX:PEGC) Headlines

No Headlines